Provided by Tiger Trade Technology Pte. Ltd.

BridgeBio Pharma, Inc.

67.25
+0.34000.51%
Post-market: 67.18-0.0738-0.11%19:30 EDT
Volume:2.65M
Turnover:178.12M
Market Cap:13.17B
PE:-18.84
High:68.68
Open:67.10
Low:66.23
Close:66.91
52wk High:93.42
52wk Low:51.85
Shares:195.81M
Float Shares:167.00M
Volume Ratio:0.88
T/O Rate:1.58%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5686
EPS(LYR):-3.7850
ROE:-1789.67%
ROA:-26.00%
PB:-5.24
PE(LYR):-17.77

Loading ...

Bridgebio Announces Publication in the New England Journal of Medicine of Phase 3 Propel 3 Trial of Oral Infigratinib in Children Living with Achondroplasia

THOMSON REUTERS
·
Jun 29

Bridgebio Shareholders Approved 2 Million-share Increase Under 2021 Equity Plan at Annual Meeting

Reuters
·
Jun 26

Bridgebio Director Hannah Valantine Disposes of Common Shares Worth $341,571.72

Reuters
·
Jun 25

BRIEF-Bridgebio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Jun 24

BridgeBio Pharma grants 66,810 restricted stock units to 30 new employees under inducement plan

Reuters
·
Jun 24

BridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jun 24

BridgeBio Oncology Therapeutics shareholders elect Lebowitz, McCormick to board

Reuters
·
Jun 23

Movement Alert|BridgeBio Pharma Rises 5.04% in Regular Trading, Trading at $69.625

Market Focus
·
Jun 23

BridgeBio to present Phase 3 PROPEL 3 trial results for oral infigratinib in children with achondroplasia at ICCBH 2026

Reuters
·
Jun 22

BridgeBio director Jennifer E. Cook disposes of common shares worth $6,011,959.36

Reuters
·
Jun 18

Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), BridgeBio Pharma (BBIO) and Guardant Health (GH)

TIPRANKS
·
Jun 17

BridgeBio Pharma Inc : Mizuho Cuts Target Price to $96 From $106

THOMSON REUTERS
·
Jun 16

U.S. RESEARCH ROUNDUP-CAMP4 Therapeutics, Rockwell Automation, Zions Bancorporation

Reuters
·
Jun 16

Analysts Offer Insights on Healthcare Companies: Alto Neuroscience, Inc. (ANRO) and BridgeBio Pharma (BBIO)

TIPRANKS
·
Jun 16

BRIEF-DKSH Enters Strategic Distribution Partnership With Bridgebio

Reuters
·
Jun 11

DKSH partners with BridgeBio to distribute ATTR-CM transthyretin stabilizer in Asia-Pacific markets

Reuters
·
Jun 11

BridgeBio CEO Neil Kumar reports $4.26 million common share disposal

Reuters
·
Jun 09

Barclays Sticks to Their Buy Rating for BridgeBio Pharma (BBIO)

TIPRANKS
·
Jun 05

How FDA Priority Review for First-in-Class LGMD Drug BBP-418 Could Impact BridgeBio Pharma (BBIO) Investors

Simply Wall St.
·
Jun 05

BridgeBio Pharma Inc : Canaccord Genuity Initiates Coverage With Buy Rating; Price Target $104

THOMSON REUTERS
·
Jun 03